A National Registry on Chinese Patients With Cystic Fibrosis

NCT05289245 · tracked via the Priya Life Science China tracker

Sponsor

Peking Union Medical College Hospital

Phase

Observational

Started

2022-04-01

Last updated

2022-03-21

Condition(s) studied

Pulmonary Function

Study summary

Cystic fibrosis (CF) is a rare autosomal recessive disease involving multiple organs, especially the lungs and digestive organs. It is most commonly seen in Caucasians. Only a few Chinese CF patients have been described in literature, taking into account the large population of China. The main objectives of this study are to accurately evaluate the prevalence of CF, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: Fulfilled WHO clinical diagnostic criteria for CF; Was in a stable phase with no respiratory infections for nearly 4 weeks; Subjects (or their guardians) signed informed consent. Exclusion Criteria: Patients with other bronchiectasis who did not meet the inclusion criteria; Those with severe cardiac or renal disease

Primary outcome measure(s)

Change in spirometry (FEV1 and FVC) of lymphangioleiomyomatosis patients. — 10 years
Spirometry will be evaluated at baseline and through study completion, an average of 3 years.

Trial sites (1)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality	Recruiting

More Peking Union Medical College Hospital trials in China

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors Recruiting

Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) Recruiting

An Observational Cohort Study to Obese Patients With Weight Cycling Active, not recruiting

A Comparative Analysis of Mid- to Long-Term Outcomes: Paclitaxel-Coated Balloon With Debulking Versus Paclitaxel-Coated Balloon Alone in the Treatment of Chronic Femoropopliteal Artery Occlusions Starting soon

Other trials for the same condition

A National Registry on Chinese Patients With Lymphangioleiomyomatosis Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05289245 on ClinicalTrials.gov ↗ ← All trials in China